Agentic AI company Owkin and Sanofi have extended their collaboration with a five-year license for K Pro, Owkin’s AI scientist, under which Owkin will lead the end-to-end development of novel, purpose-built biopharma agents for Sanofi. Owkin pitches K Pro as a system that reasons over biological data and orchestrates AI agents to run research and…
